FDA advisory panel backs RFK Jr. on unapproved peptides
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pharmacy Compounding Advisory Committee recommended Thursday that compounding pharmacies be allowed to manufacture four specific unapproved peptides: BPC-157, KPV, TB-500, and MOTS-c.
- The vote was framed as a political win for Robert F. Kennedy Jr. and peptide proponents who have advocated broader access to these compounds.
- The panel will vote on additional compounds on Friday, meaning the four named peptides are only the first tranche of decisions.
- The votes are non-binding, with the FDA making the final call on whether to lift current restrictions on the peptides.
- The source notes it is unusual for the FDA to go against PCAC recommendations, though it has happened at least once before — making the advisory vote a meaningful signal of likely FDA direction.
- The four peptides are described as "little-researched but highly popular," reflecting a gap between consumer demand and formal clinical evidence.
Why it matters: These four peptides are described as 'little-researched but highly popular' — meaning a PCAC recommendation to let compounders make them could open a regulated pathway to drugs that have largely circulated in a gray market. The FDA rarely overrides this advisory panel, so the Thursday vote is a meaningful step toward formal legitimacy for compounds that lack robust clinical trial data.
